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Pompe disease is a lysosomal storage disorder in which acid alpha-glucosidase (GAA) is
deficient or absent. Deficiency of this lysosomal enzyme results in progressive expansion
of glycogen-filled lysosomes in multiple tissues, with cardiac and skeletal muscle
being the most severely affected. The clinical spectrum ranges from fatal hypertrophic
cardiomyopathy and skeletal muscle myopathy in infants to relatively attenuated forms,
which manifest as a progressive myopathy without cardiac involvement. The currently
available enzyme replacement therapy (ERT) proved to be successful in reversing cardiac
but not skeletal muscle abnormalities. Although the overall understanding of the disease
has progressed, the pathophysiology of muscle damage remains poorly understood.
Lysosomal enlargement/rupture has long been considered a mechanism of relentless
muscle damage in Pompe disease. In past years, it became clear that this simple view
of the pathology is inadequate; the pathological cascade involves dysfunctional autophagy,
a major lysosome-dependent intracellular degradative pathway. The autophagic process in
Pompe skeletal muscle is affected at the termination stage—impaired autophagosomal-
lysosomal fusion. Yet another abnormality in the diseased muscle is the accelerated
production of large, unrelated to ageing, lipofuscin deposits—a marker of cellular oxidative
damage and a sign of mitochondrial dysfunction. The massive autophagic buildup and
lipofuscin inclusions appear to cause a greater effect on muscle architecture than the
enlarged lysosomes outside the autophagic regions. Furthermore, the dysfunctional
autophagy affects the trafficking of the replacement enzyme and interferes with its delivery
to the lysosomes. Several new therapeutic approaches have been tested in Pompe mouse
models: substrate reduction therapy, lysosomal exocytosis following the overexpression of
transcription factor EB and a closely related but distinct factor E3, and genetic manipulation
of autophagy.
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BACKGROUND AND HISTORY
Pompe disease, also known as glycogen storage disease type II
(GSDII) or “acid maltase deficiency”, is caused by the absence or
deficiency of acid alpha-glucosidase (GAA), a lysosomal enzyme
that is responsible for the cleavage of the α-1,4- and α-1,6-
glycosidic bonds of glycogen to glucose. The deficiency of the
enzyme leads to the accumulation of glycogen in the lyso-
somes in numerous tissues, but clinical symptoms are primarily
due to cardiac and skeletal muscles involvement. The disease
is characterized by a wide variety of manifestations ranging
from severe infantile-onset muscle weakness, hypotonia, and
hypertrophic cardiomyopathy to a relatively mild slowly pro-
gressive skeletal muscle myopathy in adults (Hirschhorn and
Reuser, 2001). Pompe disease is a rare disorder with an esti-
mated frequency of 1:40,000 (Martiniuk et al., 1998; Ausems
et al., 1999). The neonatal screening program for lysosomal
storage diseases (LSDs) in Taiwan and Austria using dried
blood spots revealed a higher than expected frequency of the
disease in these populations (Chien et al., 2008; Mechtler et al.,
2012).
In 1932, Johannes Cassianus Pompe, a Dutch pathologist,
described the disease in a 7-month-old infant who died of
idiopathic hypertrophy of the heart; in addition to the cardiac
problems, the infant had generalized muscle weakness. Dr. Pompe
made the crucial observation that the baby’s symptoms were
associated with massive “vacuolar” glycogen storage in virtually
all tissues; reports of similar cases appeared in literature the same
year (Bischoff, 1932; Putschar, 1932) as well as in the following
years. In 1954 the disease was classified as glycogen storage disease
type II to reflect the abnormal metabolism of glycogen (Cori,
1954). However, at that time, the cause of the disease, the “vac-
uolar” nature of the storage, and the apparent normal molecular
structure of the accumulated glycogen all remained a mystery. The
connection between lysosomes, the enzyme defect, and Pompe
disease was made much later, in 1963, by a Belgian biochemist
Henri-Gery Hers. He discovered a new enzyme (maltase) that
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carried out the hydrolysis of glycogen to glucose at an acidic pH,
and he demonstrated that the enzyme was absent in patients with
Pompe disease (Hers, 1963). By a fortunate coincidence, Dr. Hers
had been previously working in the laboratory of Christian de
Duve, who in 1955 postulated the existence of a new group
of intracellular organelles, lysosomes. Dr. Hers realized that his
new enzyme resides in the lysosomes, and that this is the only
glycogen-degrading enzyme present in the lysosomes. Based on
this research, the concept of LSDs has been established, and
the search for other missing lysosomal enzymes began. Pompe
disease became the first in a diverse group of more than 50
currently recognized lysosomal storage disorders. The cause of
Pompe disease became known 30 years after its initial description,
and it would take even longer to develop the first therapy.
GENETIC DEFECTS AND CLINICAL MANIFESTATIONS
Pompe disease comes at different ages and with different degrees
of severity. The severity of the clinical presentations, the tissue
involvement, and the age of onset generally correlate well with the
nature of the mutation and the degree of residual enzyme activity.
A database containing all the reported mutations and polymor-
phisms of the GAA gene on chromosome 17 q25 (Hoefsloot
et al., 1988, 1990; Martiniuk et al., 1990; Kuo et al., 1996)
(>300 variants) may be accessed at http://www.pompecenter.nl.
The majority of mutations are private—found only in a single
family or a small population—and most patients are compound
heterozygotes. The mutations are spread throughout the gene
and affect one of the multiple steps involved in synthesis, post-
translational modifications, lysosomal trafficking, and proteolytic
processing of GAA (see below).
The most common mutation among Caucasian children and
adults is c.-32-13T>G (IVS1), a splicing defect which allows for
the synthesis of low levels (∼10–20%) of normal enzyme (Huie
et al., 1994; Boerkoel et al., 1995; Raben et al., 1996). A study
of a large cohort of patients with a similar genotype—IVS1 in
combination with a second null mutation—unexpectedly showed
a significant variability in the age at disease onset, suggesting the
role of secondary modifying factors on the clinical course (Kroos
et al., 2012). One of the possible factors responsible for the wide
clinical variability has recently come to light: the deletion/deletion
polymorphism in the gene coding for the angiotensin-converting
enzyme (ACE), which is known to increase the number of type II
fibers and influence muscle properties, is associated with earlier
onset, higher creatine kinase (CK) levels, muscle pain, and more
severe progression of the disease in patients with adult form (de
Filippi et al., 2010).
Two mutations—c.del525T and exon18 deletion—are fre-
quent in the Netherlands (Hermans et al., 1994; Hirschhorn and
Huie, 1999), and a common defect, c.1935C>A (p.Asp645Glu),
is shared by Chinese patients in Taiwan (Shieh and Lin, 1998).
The most common mutation in African-Americans, c.2560C>T
(p.Arg854Ter), most likely originated in their ancestral popula-
tion from north-central Africa and was brought to the Americas
during the slave trade (Becker et al., 1998).
The most severe end of the phenotypic continuum is the
disease in which symptoms begin within the first months of
life, and include profound muscle weakness, hypotonia (“floppy
baby”), and hypertrophic cardiomyopathy. Massive cardiomegaly,
which is easily detectable by chest X-rays, is one of the leading
manifestations of the disease in infants. The weakness of respira-
tory muscle and cardiomegaly often lead to diminished ventila-
tion and frequent infections. Macroglossia, mild hepatomegaly,
feeding difficulties, and significantly delayed motor milestones
are also typical manifestations of this rapidly progressive form;
most patients do not survive beyond the first year of life and die
from cardiac failure. This severe subtype, described by Dr. Pompe,
is called the classic infantile form, and is caused by complete
or near complete loss of GAA activity (van den Hout et al.,
2003; Kishnani et al., 2006). Similar clinical presentations in
infants with less severe cardiomyopathy, absence of left ventric-
ular outflow obstruction, and somewhat longer survival have
been classified as a non-classical infantile form (Slonim et al.,
2000).
Partial loss of enzyme activity (residual enzyme activity
between 1 and 30%) manifests as progressive muscle dysfunc-
tion and respiratory insufficiency without cardiac involvement.
A spectrum of phenotypic variation and genotypic heterogeneity
is characteristic of this less dismal form of the disease. The
lower limbs and paraspinal muscles are frequently affected first,
followed by the respiratory muscle, particularly the diaphragm,
intercostal, and accessory muscles. As the disease progresses,
patients may develop severe scoliosis and lumbar hyperlordosis
and many become wheelchair dependent and require assisted
ventilation. Respiratory failure is the main cause of increased
morbidity and mortality (Herzog et al., 2012; Schuller et al.,
2012). Although skeletal muscle weakness dominates the clinical
picture, there is increasing evidence of the involvement of non-
muscle tissues in this group of patients (Filosto et al., 2013).
A variety of scientific terms are used in literature to describe
these different forms of the disease, such as typical and atypi-
cal infantile, non-infantile, muscular, childhood-, juvenile-, and
adult-onset, etc.; the broad term, late-onset Pompe disease
(LOPD), is often used to describe patients with muscle weakness
without cardiac involvement and the onset of symptoms after
12 months of age. However, the continuum of phenotypes often
defies categorization. Recently, the Pompe community accepted
the following proposed nomenclature: (1) “classic infantile”, as
described above; (2) “childhood” form with onset of symptoms
from birth till adolescence without persisting and progressive car-
diac hypertrophy; and (3) “adult” form with onset of symptoms
from adolescence to late adulthood (Güngör and Reuser, 2013).
ACID ALPHA-GLUCOSIDASE AND ENZYME REPLACEMENT
THERAPY (ERT)
Like many other lysosomal enzymes, GAA is synthesized in
the rough endoplasmic reticulum (ER), where high mannose
oligosaccharides are added to the 110 kDa precursor molecules,
a process known as glycosylation (Hermans et al., 1993). The
glycosylation and proper folding in the ER are essential for the
trafficking of the enzyme through the Golgi complex to the lyso-
somes. On the way to the lysosomes, the protein undergoes sugar
chain modifications and proteolytic cleavage (Wisselaar et al.,
1993). In the Golgi, the addition of the mannose-6-phosphate
(M6P) moiety (phosphorylation) allows for the recognition of
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the enzyme by (M6P) receptors, which transport the enzyme to
early and late endosomes. The Golgi is also a site for the first
proteolytic cleavage of the precursor followed by the additional
cleavage at both the amino- and carboxyl-terminal ends before
and after entry to the lysosomes (Wisselaar et al., 1993; Moreland
et al., 2005). The posttranslational modifications of the precursor
protein, a process called maturation, increase its activity of the
enzyme for glycogen (Wisselaar et al., 1993). GAA along with
other lysosomal enzymes leaves the Golgi complex in a vesicle
which delivers its content to early/late endosomes and lysosomes.
Once inside the late endosomes, the receptor-ligand complexes
dissociate due to the low pH in these vesicles, and the enzyme
is delivered to the lysosome, whereas the receptors recycle back
for the next round of sorting (Kornfeld, 1992). A portion of the
GAA precursor is secreted, and can be taken up by neighboring
cells via cation independent mannose 6-phosphate receptor (CI-
MPR) on the plasma membrane, which directs the endocytosis
and transport of the enzyme to the lysosome. The ability of cells
to secrete and internalize lysosomal enzymes, first demonstrated
in cross-correction experiments, in which normal cells rescued
the nearby deficient cells (Neufeld and Fratantoni, 1970), became
the fundamental basis of enzyme replacement therapy (ERT) for
lysosomal storage diseases, including Pompe disease.
In Pompe disease, the CHO-produced recombinant human
GAA (rhGAA; alglucosidase alpha, Myozyme®, Genzyme Corpo-
ration, Framingham, MA) is a 110 kDa precursor containing M6P
groups that enable the enzyme to bind the receptor on the cell
surface. Once inside the cell, the rhGAA, like the endogenous
precursor, is cleaved to yield intermediate and fully mature 76 and
70 kDa lysosomal forms. In 2006 the drug received broad-label
marketing approval in Europe, and later in the U.S. This is the first
therapy for GSDII, and the first attempt to direct recombinant
enzyme to skeletal muscle. This therapy is based on a straight-
forward hypothesis to explain the disease pathogenesis, namely
that the progressive enlargement of glycogen-filled lysosomes,
lysosomal rupture (due to mechanical pressure in muscle fibers),
and release of glycogen and toxic substances into the cytosol
would ultimately result in organ dysfunctions (Griffin, 1984a;
Thurberg et al., 2006). The stages and progression of skeletal
muscle damage have been described for the classical infantile
form: small glycogen-filled lysosomes in between intact myofibrils
are typical for stage 1; an increase in cytoplasmic glycogen and the
size and number of lysosomes combined with fragmentation of
myofibrils constitute stage 2; after that, glycogen-filled lysosomes
are tightly packed, some show membrane rupture, and only few
myofibril fragments remain in stage 3; finally, in stages 4 and 5,
most glycogen is cytoplasmic, the contractile elements of muscle
cells are completely lost, and the cells bloat due to the influx of
water (Thurberg et al., 2006).
The assumption was that early treatment, initiated before lyso-
somal integrity was compromised, would reverse this pathogenic
cascade and cure the disease. The outcome, however, was some-
what unexpected—cardiac muscle responded remarkably well to
therapy, but skeletal muscle did not. Even with extremely high
dosages of the drug (20–40 mg/kg body weight, which is signif-
icantly higher than in other LSDs), patients with the childhood
and adult forms of the disease experience limited clinical benefit,
such as modest improvements in walking distance and respiratory
function, but skeletal muscle weakness often persists, and some
show signs of disease progression (Van den Hout et al., 2004;
Kishnani et al., 2007; Schoser et al., 2008; Strothotte et al., 2010;
Van der Ploeg et al., 2010; Angelini and Semplicini, 2012).
The reversal of cardiac abnormalities dramatically changed the
natural course of the disease in infants; most survive significantly
longer compared with untreated group analyzed by retrospective
studies (Kishnani et al., 2007; Nicolino et al., 2009). However, the
great success of ERT in Pompe disease comes with unintended
consequences: many long-term survivors suffer from debilitating
skeletal muscle myopathy and develop new previously unrecog-
nized symptoms such as ptosis, hypernasal speech, osteopenia,
hearing loss and gastroesophageal reflux. Although the response
to therapy varies significantly in this group of patients, an
emerging pattern—initial improvement followed by a decline and
chronic disability—indicates that even at a very high doses, the
drug does not halt the progression of the disease (Chakrapani
et al., 2010; Prater et al., 2012, 2013).
One thing appears to be clear: treatment of the infants should
start within days after birth, not months (Chien et al., 2009, 2013;
Prater et al., 2013). The effect of therapy in pre-symptomatic
infants who were diagnosed through a newborn screening pro-
gram (in Taiwan) was better than in those who were diagnosed
later based on clinical symptoms (Chien et al., 2009). It is also
clear that sustained high antibody titers on ERT, particularly
in infants with cross-reactive immunological material (CRIM)-
negative status, are associated with poor outcome (Banugaria
et al., 2011).
The neonatal screening program, which allows for the early
diagnosis and timely initiation of therapy in infants, would also
identify patients with mutations that are associated with onset
of symptoms in the second, fourth or six decade of life. The
appropriate age for the initiation of therapy in patients with
milder forms of the disease is not clear, thus adding to the com-
plexity of ethical issues related to such a program. The argument
in favor of such a program for Pompe disease comes from our
own experience (however limited), which indicates that the best
morphological results are achieved when the therapy is initiated in
asymptomatic patients. A case in point is a normal muscle biopsy
after only 6 months of therapy, in an infant who was diagnosed
through the newborn screening program, but whose genetic
makeup was consistent with the childhood form of the disease; the
baseline biopsy of this asymptomatic patient with slightly elevated
CK level showed well-preserved fibers with minimally enlarged
lysosomes and no autophagic buildup (Raben et al., 2010a).
The limitations of current therapy stimulated research on
more effective second-generation drugs. The evolving new
therapies are designed to improve the delivery of the recom-
binant enzyme to skeletal muscle. The poor capacity of the
current drug to reach skeletal muscle (most of the adminis-
tered enzyme is taken by liver) has been attributed to the low
number of M6P receptors on the plasma membrane of skeletal
muscle cells. Therefore, the development of chemically modified
recombinant human GAA with high affinity for the receptor
and enhanced targeting properties is currently being pursued
by academic institutions and pharmaceutical companies (Zhu
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et al., 2009; Tiels et al., 2012; Maga et al., 2013). Albuterol,
a drug that enhances the M6P receptor expression, is also in
clinical trial in combination with ERT (Koeberl et al., 2014).
Another therapeutic approach includes the use of pharmaco-
logical chaperones to increase the stability and half-life of the
current drug (Porto et al., 2009, 2012). It is, however, unclear
how much enzyme is needed to reverse the established pathol-
ogy in Pompe skeletal muscle, and this uncertainty remains a
concern with these new approaches. It is widely believed that
the levels of ∼30% of average normal activity would be suffi-
cient, since the disease manifests when the acid α-glucosidase
activity drops below this critical threshold. However, our data
in transgenic mice expressing human GAA in skeletal muscle of
the GAA knockout mice (see Models of Pompe disease) suggest
that much higher levels might be needed for the reversal of
the advanced disease (Raben et al., 2005). The benefits of these
new strategies for enzyme delivery are beyond the scope of this
review.
GENE THERAPY
A major development in the field is the commencement of the
first phase I/II clinical trial of rAAV1-hGAA intramuscular gene
transfer. Five children with chronic ventilator dependence (full-
time mechanical ventilation despite ERT) and severe phrenic
neuromusclular dysfunction were enrolled in the trial. All patients
were on ERT, which was continued throughout the study. The
outcome of the 180-day safety and ventilatory outcomes following
intradiaphragmatic delivery of AAV-mediated GAA gene therapy
has been reported (Smith et al., 2013). The results indicated
that rAAV1-hGAA was safe and led to a modest improvement
in ventilatory function. This trial is the first critical step in the
development of a successful AAV-based gene therapy for Pompe
disease. Extensive preclinical studies (both in vitro and in vivo in
the mouse model) by a number of groups established the basis and
feasibility of gene therapy for this disorder; the reader is referred
to a review on this subject (Byrne et al., 2011). Here, we will focus
on the pathogenesis of skeletal muscle damage in Pompe disease,
which turned out to be more complex than previously thought,
and involves a profound disturbance of autophagy.
MODELS OF POMPE DISEASE
Naturally occurring animal models of Pompe disease include
cattle, dogs, cats, sheep, and Japanese quails. The underlying
genetic defects have been identified in Brahman and Shorthorn
cattle breeds in Australia, in quails (AMD quails), and Finnish
and Swedish Lapphunds. Curiously, the two Scandinavian dog
breeds, which share a common origin and physical appearance,
have been recently shown (Seppala et al., 2013) to contain a
frameshift mutation similar to that found in patients with the
infantile form of the disease (the finding points to a “hot spot”
in the GAA gene). The presence of residual GAA activity in quails
(due to the expression of other alpha-glucosidases) accounts for
the milder form of the disease, which mimics human childhood
or adult forms without cardiac dysfunction; the birds show
progressive muscle weakness, difficulty in lifting their wings or
turning from the supine position. With the development of the
knockout mouse models, the usefulness of this model became
outdated, but AMD quails deserve a special mention because
they were the first to be used for testing ERT (Kikuchi et al.,
1998).
Genotypically and phenotypically more accurate models were
made in mice by targeted disruption of exon 6 and exon 13 of the
GAA gene [GAA-KO (Raben et al., 1998) and AGLU-/- (Bijvoet
et al., 1998)]. These two models have features of both infantile
and adult forms: the animals develop cardiomegaly, cardiomy-
opathy (Bijvoet et al., 1998) and skeletal muscle myopathy, but
obvious clinical signs of the disease, such as kyphosis and muscle
wasting manifest late relative to their lifespan—at ∼7–9 months.
Both strains are widely used for testing different therapeutic
approaches. Several transgenic lines and double knockouts on the
GAA-KO background are available: GFP- LC3:GAA-KO, in which
autophagosomes are labeled with green fluorescent protein; GAA-
KO:SCID, which do not produce antibody following administra-
tion of recombinant human GAA (Xu et al., 2004); and muscle-
specific autophagy-deficient GAA-KO, which will be discussed
below.
In addition, GAA-KO crosses to H-2Kb-tsA58 transgenic mice
(also called Immortomouse; Charles River Laboratories) allowed
for the generation of an in vitro model of Pompe disease—GAA-
deficient immortalized mouse muscle cell lines. The transgene
contains the temperature-sensitive immortalizing SV40 large T
antigen tsA58 (tsA58 TAg) under the control of the interferon-
inducible H-2Kb promoter; the SV40 large T antigen is func-
tional at permissive temperature (33◦C plus interferon-γ), but
is inactivated at 37◦ in the absence of interferon. The advantage
of this system is that myoblasts derived from the GAA-KO: H-
2Kb-tsA58 mice proliferate and undergo immortalization when
the oncogene is expressed, but the differentiation of the cells to
myotubes proceeds under “normal” condition when the oncogene
is silenced (Jat et al., 1991). Unlike primary myoblasts with their
limited proliferation capacity, the immortalized cells can undergo
multiple passages without losing the ability to differentiate. The
in vitro model replicates lysosomal, but not autophagic pathology
(see below) (Figure 1; Spampanato et al., 2013), and as such
can be used to decipher the early events which precede the
development of autophagic buildup—a hallmark of the disease
in Pompe muscle fibers.
PATHOGENESIS
AUTOPHAGY
At least three autophagic pathways have been described based
on the route by which the cargo enters the lysosomes. Microau-
tophagy is a direct engulfment of cytoplasmic components into
the lysosomal lumen; in chaperone-mediated autophagy (CMA),
a subset of soluble cytosolic proteins with a particular pentapep-
tide motif are recognized by molecular chaperones and directly
translocated into lysosomes through a receptor (LAMP-2A) on
the lysosomal membrane; the major third form, most relevant
to Pompe disease, is macroautophagy, which fulfils the role of
supplying amino acids and energy under starvation by “self-
digestion” of intracellular components (Klionsky, 2007; He and
Klionsky, 2009; Yang and Klionsky, 2010; Kaushik et al., 2011).
Macroautophagy also operates at a low level under a nutrient-
rich environment to rid the cells of misfolded proteins, protein
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FIGURE 1 | In vitro model of Pompe disease replicates lysosomal, but
not autophagic pathology. The images show wild type (WT) and GAA-KO
(KO) myotubes. Immortalized myoblasts were used for the differentiation into
multinucleated myotubes. WT myoblasts were derived from mice generated
by crosses of GFP-LC3:WT to Immortomice; GAA-KO myoblasts were derived
from mice generated by crosses of GFP-LC3:GAA-KO to Immortomice. LC3
(green) is a specific autophagosomal marker. No autophagosomal
accumulation is seen in the GAA-KO cells. Myotubes were fixed and stained
for lysosomal marker LAMP1 (red). Enlarged lysosomes are seen in the
GAA-KO, but not in control WT muscle cells. Bars: 10 µm.
aggregates, and worn-out organelles such as mitochondria. Upon
induction, the process of macroautophagy (often referred to
simply as autophagy) begins with the development of a double
membrane, which engulfs part of the cytoplasm, resulting in the
formation of the double-membrane structure called autophago-
some. Autophagosomes fuses with the lysosome, where the inner
membrane and the content of the autophagosome are degraded
and recycled. The two pathways, autophagic and endocytic, by
which the recombinant human GAA traffics to the lysosomes are
interconnected; autophagosomes can fuse with early/late endo-
somes before fusion with the lysosome, giving rise to an inter-
mediate structure, called amphisome (Berg et al., 1998).
AUTOPHAGY IN POMPE MOUSE MODELS
The morphological evidence for abnormal autophagy in mus-
cle biopsies from adult Pompe patients was first reported
by Andrew Engel in 1970 (Engel, 1970), at the time when
the field of autophagy was still in its infancy. Perhaps not
surprisingly, this pathology and its contribution to the patho-
genesis of Pompe disease have been largely ignored until
recently. Studies in a GAA-KO model developed in our lab
(Raben et al., 1998) clearly demonstrated that abnormalities
in Pompe muscle cells were not limited to the enlarge-
ment of lysosomes. Analysis of myoblasts derived from GAA-
KO mice showed an acidification defect in a subset of late
endosomes/lysosomes, a dramatic expansion of all vesicles of
the endocytic/autophagic pathways, and a slowdown in the
vesicular trafficking in the overcrowded cells (Fukuda et al.,
2006).
Electron microscopy (EM) of skeletal muscle from the KO
mice revealed large areas of autophagic accumulation containing
vesicular structures at different stages of a stalled autophagic
process: small and large double-membrane autophagosomes with
undigested cytosolic material or glycogen particles, multivesicular
bodies, multimembrane structures, autofluorescent material, as
well other cellular debris (Figure 2). EM established the presence
of autophagic accumulation of Pompe muscle, but the extent
of this pathology became clear when single muscle fibers were
immunostained for lysosomal marker, LAMP1, and autophagoso-
mal marker, LC3, followed by confocal microscopy—an approach
best-suited for the detection of autophagic accumulation within
the fibers (Raben et al., 2009). Two forms of LC3 are docu-
mented: the soluble cytosolic LC3I and lipidated LC3II; the latter
remains on the autophagosomal membrane during autophagic
process and serves as a highly specific marker of autophagosomes
(Kabeya et al., 2000). LAMP1/LC3-double staining showed that
the core of the fibers was filled with clusters of densely packed late
endosomes/lysosomes and autophagosomes, collectively called
autophagic buildup. This buildup often spans the entire length
of the fibers, and in many fibers the enlarged lysosomes in the
periphery of the fibers look inconsequential (Raben et al., 2007a).
Autophagy is a dynamic multi-step process which encom-
passes autophagosome formation, maturation, fusion with lyso-
somes, and breakdown and recycling of autophagic substrates.
The term “autophagic flux” refers to the whole process—the
flux is complete if the formation of autophagosomes is followed
by their fusion with lysosomes and degradation of the cargo.
The failure of a downstream step of autophagy, fusion between
autophagosomes and lysosomes, would result in incomplete flux,
a condition known as autophagic block (Mizushima et al., 2010).
Therefore, the increase in the number of autophagosomes (as
shown by a significant increase in the LC3II levels) in Pompe
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FIGURE 2 | Electron microscopy images show the presence and the
extent (A) of autophagic buildup in skeletal muscle from a 5
month-old GAA-KO mouse. Larger magnification images (B and C)
show classical double membrane autophagosomes with undigested
cytosolic material (black arrows) or glycogen particles (arrowhead),
multimembrane structures (most prominent in C), multivesicular body
(white arrow), electron dense material (asterisk), as well other cellular
debris of unknown origin. Bars: 0.5 µm.
muscle fibers could indicate an upregulation of autophagy or
defects in autophagosome-lysosome fusion. An ubiquitin-binding
scaffold protein, p62, also known as sequestosome 1 (SQSTM1),
is commonly used as a marker of autophagic flux. The protein
accumulates in cells from autophagy-deficient mice (Komatsu
et al., 2007), and an increase in the level of p62 is an indication
of a functional deficiency of autophagy. The protein itself is a sub-
strate for autophagy-mediated degradation; in addition, p62 can
directly bind to LC3, thus connecting ubiquitinated (Ub) proteins
which are destined for degradation and autophagic machinery
(Pankiv et al., 2007; Bjørkøy et al., 2009).
The levels of potentially toxic high molecular mass
Ub-proteins in Pompe muscle were significantly increased
suggesting a failure of autophagosomal–lysosomal fusion
and a block in autophagosomal turnover. The accumulation
of Ub-proteins in the GAA-KO muscle, particularly in the
non-soluble fraction, preceded the development of clinical
symptoms and increased with age. In addition, immunostaining
of isolated muscle fibers showed that both the Ub-proteins
and p62/SQSTM1 were seen within the autophagic areas, again
indicating that the recycling process is inefficient in Pompe
skeletal muscle (Raben et al., 2008; Shea and Raben, 2009).
A direct evidence of the impaired autophagosomal-lysosomal
fusion came from time-lapse microscopy of muscle fibers
in which autophagosomes were labeled with GFP-LC3 and
lysosomes were labeled with mCherry-LAMP1. These fibers
were derived from transgenic GFP-LC3:GAA-KO mice, in which
muscles had been in vivo transfected with mCherry-LAMP1
(Figure 3). The autophagosomal-lysosomal fusion events were
essentially non-existent in the autophagic areas over the course
of several hours of time-lapse microscopy (Spampanato et al.,
2013).
The autophagic buildup containing cellular debris repre-
sents a huge non-contractile inclusion in the diseased muscle
fibers. Studies in a different mouse model of Pompe disease,
AGLU-/- (Bijvoet et al., 1998), have shown that the enlarged
lysosomes in skeletal muscle cannot adequately account for
the reduction in mechanical performance, and that the pres-
ence of large inclusions greatly contributes to the impair-
ment of muscle function (Hesselink et al., 2003; Drost et al.,
2005). Unlike sarcomeres, these inclusions are unable to gen-
erate force leading to a significant loss of force per unit of
muscle mass. It has also been shown that skeletal muscle weak-
ness in old AGLU-/- mice is caused by both loss of contrac-
tility and muscle mass (Hesselink et al., 2003; Drost et al.,
2005).
Furthermore, our data demonstrated that the autophagic
buildup affects the trafficking and delivery of the recombinant
enzyme. The fate of the therapeutic enzyme was analyzed by
monitoring the trafficking of the labeled rhGAA (Alexa-Fluor
546) in GFP-LC3:GAA-KO mice. The recombinant enzyme was
detected almost exclusively within autophagosomes clustered in
the buildup areas (Spampanato et al., 2013). This finding is not
unexpected, considering the relationship between the autophagic
pathway and the endocytic pathway; as mentioned above, the
autophagic and endocytic pathways converge not only at the
lysosome, but also at other steps along the way. It appears that
the therapeutic drug is diverted away from its intended desti-
nation, the lysosome, and instead ends up in the autophagic
area, which becomes a sink for the recombinant enzyme (Fukuda
et al., 2006; Spampanato et al., 2013). Thus, in Pompe disease,
a profoundly disordered intracellular recycling system appears
to be an important contributor to the muscle weakness and to
the incomplete response to treatment. The autophagic dead-end
found in the muscle of Pompe mice is largely limited to muscles
rich in glycolytic type II muscle fibers, which are most resis-
tant to therapy, thus confirming the link between the defective
autophagy, and the unresponsiveness to ERT with recombinant
human enzyme. Abnormal autophagy and toxicity from accumu-
lated Ub material may also be a general mechanism of cellular
damage in other lysosomal storage disorders (Lieberman et al.,
2012).
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FIGURE 3 | Confocal microscopy images of fibers from GFP-LC3:WT (A)
and GFP-LC3:GAA-KO (B) mice. In these strains autophagosomes are
labeled with green fluorescent protein. Accumulation of autophagosomes
(green) can be seen in live unstained muscle fibers derived from GAA-KO,
but not from WT mice. Muscle was transfected in vivo by electroporation
with mCherry-LAMP1 to visualize lysosomes (red); fibers were isolated
6 days after the procedure. (A) Autophagosomes are not detectable in the
control muscle. (B) This still image shows autophagic buildup in the core of
a fiber from the diseased muscle. Time-lapse microscopy of
mCherry-LAMP1 transfected fibers demonstrated that there is little, if any,
fusion between lysosomes and autophagosomes in the areas of autophagic
buildup. Bar: 10 µm.
AUTOPHAGY IN POMPE PATIENTS
The apparent disconnect between the findings in Pompe mice,
in which dysfunctional autophagy seemed to be a prominent
feature of skeletal muscle pathology, and the morphological data
(described above) on the stages of the disease progression in
infants (Thurberg et al., 2006) raised some skepticism regarding
the relevance of mouse studies to human disease. A closer look at
muscle biopsies of untreated patients with severe classic infantile
form aimed specifically to detect autophagy (namely, immunos-
taining of isolated fibers for lysosomal and autophagosomal
markers) showed that, indeed, the overwhelming characteristic
of muscle fibers in infants was the presence of hugely expanded
lysosomes often without clear borders, a feature consistent with
the long-held hypothesis of lysosomal rupture and the release
of glycogen and lytic enzymes into the cytoplasm as a cause of
muscle destruction (Griffin, 1984b; Thurberg et al., 2006).
However, analyses of muscle biopsies from patients with
milder childhood/juvenile and adult forms of the disease justified
the role of autophagy as a critical player in the pathogenesis of
Pompe disease in this subset of patients. The pathological changes
in many muscle fibers from these patients, even more so than in
mice, reflected the autophagic abnormalities leading to muscle
destruction. Large autophagic buildup often dwarfs the enlarged
glycogen-filled lysosomes that lie outside the autophagic region,
and in some fibers the buildup appears to be the only pathology
(Raben et al., 2007b; Lewandowska et al., 2008; Raben et al.,
2010a); unlike in mice, there is no selective involvement of the
different histochemical fiber types. Similar to the findings in the
murine model, the defective autophagic flux in muscle of patients
with these forms impinges on the maturation of GAA and the
uptake of recombinant enzyme during ERT (Nascimbeni et al.,
2012a,b).
Notably, autophagic accumulation, closely resembling that in
children and adults, becomes prominent (although limited in
size) in infants who benefit most from ERT and survive beyond
infancy (Raben et al., 2010a). The autophagic buildup in muscle
biopsies from these patients is usually seen in fibers with minimal
or no lysosomal enlargement outside the autophagic area, sug-
gesting that the therapeutic enzyme reached these lysosomes, and
digested the accumulated glycogen. The emergence of autophagic
buildup on therapy is clearly not a “side effect” of the treatment,
but rather an indication that the drug reverses the pathology only
partially, and leaves a subset of lysosomes that are unable to fuse
with the autophagosomes. It remains unclear to what extent this
autophagic buildup could grow in size in patients on therapy;
it is also not clear whether the clinical decline is caused by this
emerging pathology.
LIPOFUSCINOSIS
There is yet another abnormality in both untreated and treated
children and adults as well as in treated infants which recently
came to light: muscle biopsies in the majority of patients contain
large, irregularly shaped autofluorescent inclusions (Figure 4). In
some patients, more than 75% of fibers contained these struc-
tures, which can span up to several hundred microns along the
length of the fiber. These structures are usually located in the
area of autophagic buildup within LAMP-positive lysosomes or
LAMP/LC3-double positive autolysosomes (vesicles formed by
autophagosomal-lysosomal fusion) or free in the cytoplasm. Their
characteristics—electron density, contrast in transmitted light, a
wide-spectrum of autofluorescence, which is quenched by Sudan
Black B, and positive staining for lipid markers—unequivocally
identify the particles as lipofuscin (Schoser et al., 2007; Feeney
et al., 2014). Similar inclusions, although much smaller in size,
have been found in muscle of old knockout mice.
Lipofuscin is an autofluorescent lipopigment, which is com-
posed of highly cross-linked undegradable protein aggregates,
lipids, carbohydrates, and metals (particularly iron) (Terman
et al., 2010). Gradual intralysosomal accumulation of lipofuscin,
particularly in terminally differentiated cells (i.e., neurons, retinal
pigment epithelium, cardiac myocytes, and muscle cells) is a
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FIGURE 4 | Autofluorescent lipofuscin inclusions in a muscle biopsy
from a patient (NBSL9a) with a childhood form of Pompe disease. The
patient was diagnosed during a family study and began therapy at 7 years of
age. The biopsy was taken prior to the initiation of ERT. Bar: 10 µm.
characteristic sign of cellular oxidative damage and aging (Brunk
and Terman, 2002; Terman and Brunk, 2006; Terman et al.,
2006). Given the unique role of autophagy and lysosomes in
mitochondrial degradation, the diminished degradative capacity
of lysosomes due to the progressive deposition of lipofuscin in
these organelles would lead to a decrease in the autophagic turn-
over of damaged mitochondria, which in turn would result in the
generation of reactive oxygen species and formation of oxidized
proteins and aggregates, thus perpetuating the production of
lipofuscin. In addition, intralysosomal accumulation of lipofuscin
affects the trafficking of the newly synthesized lysosomal enzymes,
thus further diminishing the degrading capacity of the lysosomes.
This “vicious circle” of mitochondrial oxidative damage and
lysosomal deposition of lipofuscin is at the heart of a well-known
“mitochondrial-lysosomal axis theory of ageing”, which was put
forward by Ulf Brunk and Alexei Terman (Brunk and Terman,
2002). According to this model, accumulation of “biological
garbage” results from the natural decline in the ability of the
cellular degradative machinery to efficiently clear the cells from
damaged structures (Terman et al., 2010).
The view of lysosomes as the only site for lipofuscin formation
has been recently challenged; it was shown that inhibition of
autophagy and reduced lysosomal uptake of protein aggregates
did not prevent the formation of lipofuscin, suggesting that
lipofuscin can be formed in the cytoplasm (Höhn et al., 2012).
If lysosomes are not required for the formation of lipofuscin, then
their engulfment by autophagosomes may serve as a protective
mechanism designed to mitigate the toxicity (Höhn et al., 2014).
In Pompe skeletal muscle, lipofuscin deposits are seen both inside
and outside of lysosomes/autophagosomes; the presence of free
cytoplasmic lipofuscin may reflect its extralysosomal formation
or release into cytoplasm due to lysosomal rupture. Whatever the
origin, these deposits are strikingly large in size (Figure 4) and are
not associated with advanced age; they are seen in muscle biopsies
from patients at different ages, including very young children
(Schoser et al., 2007; Raben et al., 2010a; Feeney et al., 2014).
In retrospect, the reported in literature abnormal inclu-
sions in muscle biopsies from Pompe patients—called “reducing
body-like inclusions”, “peculiar globular inclusions”, “autofluores-
cent balloon-like structures”, “acid phosphatase-positive globular
inclusions”—all represent lipofuscin (Jay et al., 1992; Sharma
et al., 2005; Raben et al., 2010a; Tsuburaya et al., 2012). Given
the reduced autophagic activity and a failure of autophagosomal
turnover, the presence of lipofuscin in the diseased muscle is
not unexpected, but the magnitude of this pathology is. Inter-
estingly, lipofuscin inclusions are often seen in otherwise normal
looking fibers. It was suggested that these acid phosphatase-
positive/periodic acid Schiff (PAS)-negative inclusions may be
a hallmark of the disease and a diagnostic marker, particularly
in adult form, which every so often represent the diagnostic
challenge (Tsuburaya et al., 2012; Fujimoto et al., 2013).
Thus, our view of the pathogenesis of skeletal muscle damage
in Pompe disease (at least in milder childhood and adult forms)
evolved from a simple idea of gradual glycogen accumulation and
lysosomal expansion to a much more complex picture, which
involves a profound dysregulation of autophagy, accumulation
of potentially toxic undegradable materials and non-contractile
inclusion, as well as oxidative stress. Mitochondrial abnormalities,
no doubt, contribute to the pathogenic cascade (our unpublished
data). The disease has the characteristics of autophagic myopathy,
premature “muscle ageing” or “muscle lipofuscinosis”.
The evolution of our understanding of the pathogenesis of
muscle destruction in Pompe disease reflects to a large degree
the expansion of the role of the lysosomes themselves. The days
of looking at the lysosomes as cellular “garbage disposal unit”
or “suicide bags” [the latter term used by Christian de Duve
who discovered this organelle (Appelmans et al., 1955)] are long
gone. Lysosomes are now viewed more like “the center of cellular
universe” (Walkley, 2008). In addition to their role in the diges-
tion and recycling of various extra- and intracellular materials,
lysosomes carry multiple tasks—they are implicated in choles-
terol homeostasis, plasma membrane repair, tissue remodeling,
pathogen defense, MHC class II antigen presentation, down-
regulation of surface receptors, and cell death and proliferation
(Saftig and Klumperman, 2009). Furthermore, recent studies
indicate that lysosomes control their own biogenesis and provide
a platform for both activation and deactivation of mTORC1
(mechanistic target of rapamycin complex1), a powerful anabolic
regulator of cell growth and metabolism (Zoncu et al., 2011; Bar-
Peled and Sabatini, 2014; Demetriades et al., 2014; Menon et al.,
2014; Settembre and Ballabio, 2014).
EXPERIMENTAL APPROACHES TO THERAPY
SUBSTRATE REDUCTION THERAPY (SRT)
Successful application of SRT to other lysosomal diseases (Hollak
and Wijburg, 2014) stimulated efforts to test a similar approach
in Pompe disease. Inhibition of the two major enzymes involved
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in glycogen synthesis, glycogenin (GYG) and glycogen synthase
(GYS), in primary myoblasts from GAA-KO mice by shRNAs
resulted in a decrease in cytoplasmic and lysosomal glycogen
accumulation and a reduction in the lysosomal size. A single
intramuscular injection of recombinant AAV-1 vectors expressing
shGYS into newborn knockout mice led to a significant reduction
of glycogen accumulation in skeletal muscle (Douillard-Guilloux
et al., 2008). Furthermore, genetic inactivation of GYS1 in the
GAA-KO mice reversed cardiac abnormalities, reduced glycogen
storage and autophagic buildup, and improved exercise capacity
(Douillard-Guilloux et al., 2010). Of note, the disruption of GYS1
(muscle form) in the wild type mice (known as MGSKO) leads
to abnormal cardiac development and a severe early perinatal
mortality; 90% of GYS1-null pups die due to impaired cardiac
function (Pederson et al., 2004). However, the lack of glycogen in
skeletal muscle in the surviving 10% mice does not affect either
the morphology of this tissues or the animals’ ability to exercise.
A severe deficiency of muscle glycogen synthase (mutations in the
GYS1 gene; glycogen storage disease type 0), leading to cardiac
arrest, has been described in several families (Kollberg et al., 2007;
Cameron et al., 2009; Sukigara et al., 2012), thus highlighting
the risk of GYS1 suppression in Pompe disease—only muscle-
targeted inhibition of GYS1 can be considered.
FIBER TYPE CONVERSION
A selective resistance of glycolytic type II muscle fibers (fast
muscle) to ERT in the GAA-KO mice combined with massive
accumulation of autophagic debris in these fibers suggested that
a switch from fast to slow fibers may be beneficial in Pompe
disease. A successful fiber type conversion was achieved by
transgenic expression of PGC-1α—a transcription factor that
promotes mitochondrial biogenesis and muscle remodeling (Lin
et al., 2002)—in skeletal muscle of the GAA-KO mice. The con-
version of fast muscle into muscle with slow metabolic profile
restored autophagic flux, reduced the amount of accumulated
Ub-proteins, and completely eliminated autophagic buildup. The
absence of buildup was unexpectedly associated with induc-
tion rather than suppression of autophagy, as shown by a
significant upregulation of several autophagy-related proteins,
such as LC3II, GABARAP, Beclin-1, and BNIP3. A concomitant
dramatic increase in the number of lysosomes in the PGC-1α-
overexpressing muscle accounts for this apparent paradox. How-
ever, overexpression of PGC-1α in the diseased muscle failed to
improve the ERT, mainly because of the considerable increase in
the lysosomal glycogen load (Takikita et al., 2010). Although dis-
appointing, these results are interesting in two respects: (1) a slight
PGC-1α-induced increase in the levels of cytoplasmic glycogen
(seen in wild type muscle) leads to a massive accumulation of
lysosomal glycogen in GAA-deficient muscle, suggesting a high
rate of lysosomal glycogen disposal in skeletal muscle. This may
explain a much higher requirement for the therapeutic drug
in skeletal muscle than in the heart; and (2) the biogenesis of
lysosomes and autophagosomes is regulated coordinately.
SUPPRESSION OF AUTOPHAGY IN SKELETAL MUSCLE
The association between autophagic buildup and resistance to
therapy in Pompe skeletal muscle suggested that suppression
of autophagy would be helpful. Since autophagy is a presumed
mechanism of glycogen transport to the lysosomes (Schiaffino
and Hanzlikova, 1972; Kotoulas et al., 2006; Schiaffino et al.,
2008), this approach also had a potential to reduce or even
eliminate lysosomal glycogen accumulation. The genetic suppres-
sion of autophagy in GAA-KO mice was achieved by selective
inactivation of a critical autophagic gene, Atg7, in skeletal muscles
(Atg7/GAA double knockout). Indeed, inactivation of autophagy
resulted in a significant decrease in the amount of accumulated
glycogen, supporting the idea that autophagic pathway is at least
partially responsible for the delivery of glycogen to the lysosomes;
microautophagy could be another route by which glycogen enters
the lysosome. As expected, autophagic buildup was not observed
in the double knockout mice, although small clusters of double-
membrane vesicles were detected by electron microscopy. In our
experience, the phenotype of these muscle-specific autophagy-
deficient GAA-KO mice is not worse (if not better) compared to
that of the GAA-KO; however, an assessment of muscle strength
by functional tests are needed to clarify this point (Raben et al.,
2010b). The loss of autophagy alone in skeletal muscle of wild
type mice is associated with the accumulations of dysfunctional
mitochondria, mild atrophy, and age-dependent decrease in mus-
cle strength (Masiero et al., 2009; Wu et al., 2009; Masiero and
Sandri, 2010). The negative effects of suppression of autophagy in
the GAA-KO mice are likely balanced by the beneficial effect of
glycogen reduction.
Inactivation of a different autophagic gene, Atg5, in skeletal
muscle of the GAA-KO mice, led to a modest glycogen reduction
and worsening of clinical manifestations: these Atg5/GAA double
knockouts develop early signs of muscle wasting and do not sur-
vive beyond 9–12 months of age (both GAA-KO and Atg7/GAA-
KO have near normal lifespan) (Raben et al., 2008). The reason
for the difference between the two double knockouts (expected to
be indistinguishable), is not clear; a various degree of autophagy
inactivation due to the difference in the promoters, which were
used to excise the autophagic genes (human skeletal actin for
the Atg5 and myosin light chain for the Atg7), may explain the
discrepancy. However, both autophagy-deficient GAA-KO strains
responded remarkably well to ERT—a near complete removal of
stored lysosomal glycogen was observed in skeletal muscle—an
outcome never seen in the ERT-treated GAA-KO mice. These data
established the rational for autophagy-targeted therapy (Raben
et al., 2010b).
STIMULATION OF LYSOSOMAL EXOCYTOSIS
Perhaps the most intriguing approach is that which exploits
the intrinsic property of lysosomes to undergo regulated exo-
cytosis. The process involves translocation and docking of lyso-
somes to the plasma membrane, followed by fusion with the
membrane and release of the lysosomal content into the extracel-
lular space. Initially ascribed to a subset of secretory lysosome-
related organelles in hematopoietic cells or melanocytes, this
calcium-dependent process is now attributed to all conventional
lysosomes—a finding that changed the view of lysosomes as a
terminal, dead-end degradation compartment (Andrews, 2000).
Furthermore, this ability of lysosomes to exocytose is now seen as
an integral part of the lysosomal function—to accomplish cellular
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clearance by degrading the cargo or by discharging it (Settembre
and Ballabio, 2014). However, it was not until the discovery of
transcription factor EB (TFEB) that the induction of lysosomal
exocytosis became a therapeutic strategy in a variety of lysosomal
storage disease and disorders with accumulation of abnormal
proteins (Sardiello et al., 2009; Medina et al., 2011; Settembre and
Ballabio, 2011).
The bHLH-leucine zipper TFEB, a master regulator of lyso-
somal biogenesis and autophagy, has been shown to stimulate
the generation of new lysosomes and autophagosomes, and to
promote fusion of lysosomes with autophagosomes and plasma
membrane in a variety of cell types (Sardiello et al., 2009; Settem-
bre and Ballabio, 2011; Settembre et al., 2011). The mechanism of
TFEB-mediated gene regulation involves its ability to directly bind
a 10-base pair sequence (called CLEAR: Coordinated Lysosomal
Expression and Regulation) in the promoter regions of many
lysosomal and autophagic genes (Sardiello et al., 2009).
Indeed, overexpression of TFEB in both GAA-KO mice and
cultured Pompe muscle cells reduced glycogen load and lyso-
somal size, improved autophagosome processing, and alleviated
excessive accumulation of autophagic vacuoles, thus establishing
TFEB as a valid therapeutic target in Pompe disease. Lysosomal
docking/fusion with the plasma membrane was visualized during
time-lapse microscopy of live muscle fibers isolated from TFEB-
treated GAA-KO mice (Feeney et al., 2013; Spampanato et al.,
2013). More recent studies showed that a closely related but
distinct transcription factor E3 (TFE3) is another target (perhaps
even more attractive) since it is abundant in skeletal muscle,
whereas TFEB is not. Similar to TFEB, TFE3 binds to the CLEAR
elements in the promoter region of multiple lysosomal genes
(Martina et al., 2014a,b). Furthermore, mapping TFE3 binding
sites across the genome in the wild type muscle cells by ChIP-seq
analysis showed similarity to known TFEB binding locations (our
unpublished data). Overexpression of TFE3 induced lysosomal
exocytosis and promoted glycogen clearance in Pompe muscle
cells (Martina et al., 2014b).
The appeal of TFEB or TFE3 modulation as a therapeutic
option in Pompe disease is twofold: (1) this approach circumvents
the major hurdle of the current therapy—inefficient enzyme
delivery to skeletal muscle; and (2) unlike other efforts, it restores
autophagic flux and addresses both lysosomal and autophagic
pathologies.
CONCLUSION AND FUTURE STUDIES
The limitations of enzyme replacement therapy in Pompe disease
have led to reassessment of the basic skeletal muscle pathology,
which in turn uncovered new pathogenic mechanisms, in partic-
ular the role of autophagy. This new understanding allowed for
the identification of novel therapeutic targets that hopefully will
guide us toward the development of fresh strategies independent
of or complementary to ERT.
In spite of all the advances, many questions still remain.
The signaling pathways which are linked to the lysosomes are
still an unexplored area in Pompe disease. Recent findings have
positioned the lysosome at the center of the mTORC1 signaling
pathway; mTORC1 is a protein kinase complex that functions as a
central regulator of cellular growth and metabolism by integrating
signals from nutrients, energy, and growth factors (Zoncu et al.,
2011; Bar-Peled and Sabatini, 2014). A skeleton explanation of the
activation and inhibition of the mTORC1 is as follows. Accumu-
lation of amino acids in the lysosomal lumen initiates a signal
to a multiprotein lysosome-based complex, which culminates in
the mTORC1 recruitment to the lysosome where it is activated
by Rheb (Ras homolog enriched in brain). The recruitment and
activation of mTORC1 depends on the nucleotide-bound state
of the Rags (Bar-Peled and Sabatini, 2014). The inhibition of
lysosomal function or depletion of amino acids from the lysosome
results in the release of mTORC1 from the lysosome and its
inactivation (Zoncu et al., 2011). Perhaps even more relevant to
Pompe disease is the data indicating that the Rag family also
signals glucose concentration to mTOR; in other words, glucose,
like amino acids, controls mTORC1 recruitment to the lysosomal
surface and its activation (Efeyan et al., 2013).
Activation of mTORC1 also induces phosphorylation of TFEB
and TFE3 and their retention in the cytosol where these tran-
scription factors remain inactive; inhibition of phosphorylation
(for example, by nutrient deprivation) stimulates their nuclear
translocation and activation leading to the induction of multiple
target gens including lysosomal genes (Settembre et al., 2011;
Martina et al., 2012; Settembre et al., 2012; Martina et al., 2014b).
Thus, the lysosome regulates its own biogenesis by a lysosome-
to-nucleus signaling mechanism (Settembre et al., 2012). There-
fore, pharmacological inhibition of TFE3 phosphorylation would
promote cellular clearance in Pompe disease as well as in other
lysosomal storage disorders. The regulation of TFEB and TFE3
in skeletal muscle in general and in Pompe disease in particular
remains an open question. This is a rewarding field for future
studies.
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